Eli Lilly ’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two…#zepbound #elilillys #newyorkcity #elililly #fda #osa #pap #jeffemmick #mounjaro #medicare
Source: Reuters: Health - Category: Consumer Health News Source Type: news